La chaîne d'options affiche les données clés des options sur actions de 4D Molecular Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour 4D Molecular Therapeutics..

4D Molecular Therapeutics (NASDAQ:FDMT) Stock, Chaîne d'Options

4D Molecular Therapeutics

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics Inc

<ul>
<li>Leading institutional investors participated in this financing, including funds and accounts managed by BlackRock</li>
<li>The additional $300M in equity capital reinforces its already strong financial position as it eyes strong demand in the defense market and beyond for its planned hybrid aircraft
<ul>
<li>Archer has long maintained one of the strongest balance sheets in its industry, and this additional capital further strengthens its position bringing its total liquidity to ~$1 billion</li>
</ul>
</li>
</ul>

News

Financing

ACHR

Archer Raises $301.75M From Leading Institutional Investors To Accelerate Hybrid Aircraft Platform Development

Contracts

CJMB

Callan JMB Has Been Awarded A Second Five-Year Contract By The Oregon Health Authority For Medical Emergency Preparedness And Response Services

Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) shares are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading higher</a> following better-than-expected fourth-quarter earnings results.
The company reported fourth-quarter sales growth of 6% year-on-year to $11.5 billion, beating the analyst <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43618735/coca-cola-reports-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">consensus estimate of $10.677 billion</a>.
Revenue performance included a 5% climb in concentrate sales and a 9% growth in price/mix. Unit case volume grew 2% in the quarter. Organic revenues increased 14%.
Coca-Cola&#8217;s organic revenue in Europe, Middle East and Africa jumped 17% in the fourth quarter, while in North America, it increased 15%.
Gross profit rose 12% to $6.93 billion with a <a target="_blank" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000021344/000002134425000005/ko-20250211.htm" rel="noreferrer noopener">profit margin of 60%</a>. The operating margin expanded 250 basis points to 23.5%, while the comparable operating margin gained 90 basis points to 24%.&nbsp;
Operating income for the quarter increased 19.2% to $2.7 billion. Adjusted EPS of $0.55<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener"> beat the consensus</a> estimate of $0.52.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/management/25/02/43617258/southwest-airlines-taps-tom-doxey-as-cfo-details" rel="noreferrer noopener">Southwest Airlines Taps Tom Doxey As CFO: Details</a>
Operating cash flow generated for twelve months was $6.8 billion, a 41% decrease from the prior year. Free cash flow totaled $4.7 billion. KO held $14.5 billion in cash and equivalents as of December&nbsp;end.
In 2024, the company issued $0.7 billion of shares in connection with the exercise of stock options by employees and purchased $1.8 billion of shares.
&#8220;Our all-weather strategy is working, and we continue to demonstrate our ability to lead through dynamic external environments,&#8221; said Chairman and CEO James Quincey.
Outlook: Coca-Cola expects FY25 organic revenue of 5% &#8211; 6%. KO sees comparable currency neutral EPS growth of 8% – 10%. The company anticipates comparable EPS growth of 2% – 3%.
Coca-Cola sees free cash flow excluding the fairlife contingent consideration payment (non-GAAP) of approximately $9.5 billion.
For first-quarter, comparable net revenues are expected to include a 3% to 4% currency headwind.
Price Action: KO shares are trading higher by 4.71% at $67.52 in premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43599121/hyatt-hotels-to-acquire-playa-hotels-resorts-in-26b-deal" target="_blank" rel="noreferrer noopener">Hyatt Expands All-Inclusive Empire With $2.6 Billion Playa Deal: Asset-Light Strategy In Focus</a></li>
</ul>
Image via Shutterstock.

Earnings

Equities

Large Cap

Guidance

Movers

Trading Ideas

General

Coca-Cola Pops In Q4—Revenue Soars 6%, CEO Hails 'All-Weather Strategy'

Biotech

FEMY

Femasys Achieves UK Regulatory Approval For FemaSeed For Female Infertility Treatment And Two Diagnostic Devices

Stephens &amp; Co. analyst Jeff Lick maintains Asbury Automotive Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABG#NYSE">ABG</a>) with a Equal-Weight and raises the price target from $220 to $260.

Price Target

Analyst Ratings

Stephens & Co. Maintains Equal-Weight on Asbury Automotive Gr, Raises Price Target to $260

BMO Capital analyst Etzer Darout downgrades Q32 Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) from Outperform to Market Perform and lowers the price target from $22 to $3.

Downgrades

QTTB

BMO Capital Downgrades Q32 Bio to Market Perform, Lowers Price Target to $3

NIVFW

Trading Halt: Halt status updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

JP Morgan analyst Brian Essex maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Neutral and lowers the price target from $42 to $40.

JP Morgan Maintains Neutral on Rapid7, Lowers Price Target to $40

JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NASDAQ">CLBT</a>) with a Overweight and raises the price target from $24 to $28.

CLBT

JP Morgan Maintains Overweight on Cellebrite DI, Raises Price Target to $28

WIIM

Organigram shares are trading lower. The company reported Q1 financial results.

JP Morgan analyst Brian Essex maintains CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Overweight and raises the price target from $375 to $431.

CYBR

JP Morgan Maintains Overweight on CyberArk Software, Raises Price Target to $431

Macro Economic Events

Econ #s

Economics

US Redbook (YoY) 5.3% Vs 5.7% Prior

Hedge Funds

Elliott Investment Management Discloses $2.5B+ Position In Phillips 66 And Sends Letter To Board

DOMH

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

ENV105 can potentially address resistance in a wide range of cancers as they become resistant to standard treatments.

KAPA

Kairos Pharma Adds Huntsman Cancer Institute For Phase 2 Clinical Trial Of ENV105

LIXT

Lixte Biotechnology shares are trading lower after the company announced a registered direct offering valued at approximately $1.05 million.

JP Morgan analyst Peter Peng maintains Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) with a Overweight and lowers the price target from $42 to $30.

AMKR

JP Morgan Maintains Overweight on Amkor Tech, Lowers Price Target to $30

HTBI

HomeTrust Bancshares,To Transfer Listing To NYSE; To Change Ticker To "HTB"

LIPO

Lipella Pharmaceuticals shares are trading higher after the company announced a favorable safety profile for its Phase 2a results of LP-310 for the treatment of oral lichen planus.

HYLN

Hyliion Signs LOI With Al Khorayef To Deploy KARNO Generators In Saudi Arabia

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report), wi...

H.C. Wainwright Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)

Barclays analyst Gena Wang maintained a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report) today and set a price target of $45.00. Th...

4D Molecular Therapeutics (FDMT) Receives a Buy from Barclays

Analyst Matthew Caufield of H.C. Wainwright reiterated a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report), retaining the price targ...

4D Molecular Therapeutics: Strong Buy Rating on Promising 4D-150 Gene Therapy Data and Strategic Phase 3 Trials

In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Hold rating on 4D Molecular Therapeutics (FDMT – Research Report), w...

Cautious 'Hold' Rating on 4D Molecular Therapeutics Amidst Competitive Market and Investor Concerns

4D Molecular (FDMT) presented 52-week wet age-related macular degeneration Phase IIb results at this weekend's Angiogenesis, Exudation, and Degener...

4D Molecular's wAMD drug is best-in-class, says RBC, sees 'ideal' entry point

RBC Capital analyst Lisa Walter reiterated a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report) today and set a price target of $39.0...

4D Molecular Therapeutics (FDMT) Gets a Buy from RBC Capital

In a report released yesterday, Geulah Livshits from Chardan Capital maintained a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report),...

Chardan Capital Keeps Their Buy Rating on 4D Molecular Therapeutics (FDMT)

Chardan lowered the firm's price target on 4D Molecular (FDMT) to $30 from $39 but keeps a Buy rating on the shares following the company's interim...

4D Molecular price target lowered to $30 from $39 at Chardan

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pacific Biosciences (PACB – Research Report), Immu...

Analysts Offer Insights on Healthcare Companies: Pacific Biosciences (PACB), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Globus Medical (GMED – Research Report) and 4D Mol...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Globus Medical (GMED) and 4D Molecular Therapeutics (FDMT)

ADVM

FDMT

GMED

IMVT

PACB

Press Releases

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV

Health Care

4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS

4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway

4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

Abeona Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

4D Molecular Therapeutics

4D Molecular Therapeutics (FDMT) Options

4D Molecular Therapeutics (NASDAQ:FDMT) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL